The Macanda team is energized after a few intense and insightful days at ISPOR Europe in Barcelona. The impact of AI, the EUHTA regulation, and RWE were the central themes of this year’s program and on-the-ground discussions.
The promise of AI continues to grow, but its practical implementation remains limited by challenges such as data confidentiality, data security, and output validity. Most stakeholders agree that in the coming years, supervised AI will make workflows more efficient, enabling us humans to explore new capabilities and expand the scope of what is possible. While the ISPOR presentations were often high-level, the practical use cases were a hot topic on the conference floor.
Unlike the AI sessions, several ISPOR workshops provided concrete examples of how RWE can be integrated into reimbursement applications. We are closely following developments in HTA-agency guidelines and staying updated on how European agencies approach RWE acceptance.
With the JCA process set to begin in just two months, many stakeholders, including national agencies, are not fully prepared. Gaps in infrastructure and unresolved questions remain, underscoring the need for collaboration. We anticipate a phase of iteration and “learning by doing” to align processes effectively.
While progress is evident, we had expected to see more concrete developments compared to last year’s conference.
By next year’s ISPOR, we hope to look back at 2025 with hands-on learnings from the first JCA cases, a clear path forward, and new use cases for AI in health economics, real-world evidence, and market access workflows.
The Macanda team is fully engaged in these transformative developments. Reach out to us at contact@macanda.se if you’d like to discuss the implications for your products and market access strategy in the Nordics.
